We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

52 hedge funds and large institutions have $149M invested in CERo Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 4

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

16% more funds holding

Funds holding: 45 → 52 (+7)

9% more capital invested

Capital invested by funds: $137M → $149M (+$11.8M)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

Holders
52
Holders Change
+7
Holders Change %
+15.56%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
12
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
+$5.01M
2
WCMNY
Westchester Capital Management (New York)
New York
+$4.63M
3
SCM
Saba Capital Management
New York
+$3.99M
4
FTCM
First Trust Capital Management
Illinois
+$3.52M
5
WP
Woodline Partners
California
+$2.74M

Top Sellers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
-$12.3M
2
Citadel Advisors
Citadel Advisors
Florida
-$7.5M
3
MI
MMCAP International
Cayman Islands
-$3.81M
4
WAM
Weiss Asset Management
Massachusetts
-$2.6M
5
OMC
Old Mission Capital
Illinois
-$152K
Name Holding Trade Value Shares
Change 		Change in
Stake
NAM
26
Nexpoint Asset Management
Texas
$2.18M – – –
UOC
27
UBS O'Connor
Illinois
$2.11M +$2.1M +105 New
CH
28
CVI Holdings
Delaware
$2.07M – – –
WAM
29
Weiss Asset Management
Massachusetts
$2.06M -$2.6M -130 -56%
Hudson Bay Capital Management
30
Hudson Bay Capital Management
Connecticut
$2.01M – – –
SRCM
31
Sage Rock Capital Management
New York
$1.84M +$1.84M +92 New
PMAM
32
Picton Mahoney Asset Management
Ontario, Canada
$1.5M – – –
Janus Henderson Group
33
Janus Henderson Group
United Kingdom
$1.3M +$1.3M +65 New
Barclays
34
Barclays
United Kingdom
$1.06M – – –
KL
35
KIM LLC
Kansas
$1M +$1M +50 New
TCM
36
Tenor Capital Management
New York
$1M – – –
BI
37
Bulldog Investors
New Jersey
$993K -$100K -5 -9%
SSA
38
Schonfeld Strategic Advisors
New York
$952K +$40.1K +2 +4%
RCM
39
Rivernorth Capital Management
Florida
$501K – – –
WA
40
Whitebox Advisors
Minnesota
$501K – – –
CC
41
Centiva Capital
New York
$422K +$421K +21 New
LCM
42
Lynwood Capital Management
Ontario, Canada
$347K +$40.1K +2 +13%
DFCM
43
Dark Forest Capital Management
Puerto Rico
$320K – – –
SC
44
Sculptor Capital
New York
$294K +$20K +1 +7%
DCM
45
Dupont Capital Management
Delaware
$251K – – –
CM
46
Crestline Management
Texas
$251K +$260K +13 New
SV
47
Starboard Value
New York
$213K – – –
HF
48
HRT Financial
New York
$135K – – –
DAM
49
Deltec Asset Management
New York
$100K – – –
RCM
50
Robinson Capital Management
Michigan
$65K +$60.1K +3 New
1
2
3

CERO Hedge Fund Activity: Q2 2022 in Review

52 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q2 2022, worth a combined $149M — up 8.6% from $137M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new CERO positions and 5 closed out — a net gain of 7 holders — while 12 added to existing stakes and 4 trimmed.

The largest buyer was HGC Investment Management, adding an estimated $5.01M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $12.3M sold.

  • 52 institutional investors held CERo Therapeutics (CERO) as of Q2 2022, up from 45 in Q1 2022.
  • Funds reported $149M of CERo Therapeutics stock for Q2 2022, up 8.6% quarter-over-quarter.
  • 12 funds opened new CERo Therapeutics positions in Q2 2022 and 5 closed out, a net change of +7 holders.
  • The largest CERo Therapeutics buyer in Q2 2022 was HGC Investment Management, an estimated $5.01M added.
  • The largest CERo Therapeutics seller in Q2 2022 was Beryl Capital Management, an estimated $12.3M sold.

Based on aggregated 13F filings for Q2 2022.